VivoSeq
Other

Epistaxis

12

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Epistaxis is an emerging landscape with 12 programs across 4 companies. The most active players are Kenvue Brands, Pfizer, Amring. 5 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

81/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kenvue Brands

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2A

Amring

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

14 of 15 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed13 · 76%
Terminated2 · 12%
Suspended1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Tranexamic Acid Versus Blood Stopper Treatments in Epistaxis Management
Not yet recruiting·—·Phase 4·NCT06490653·186 enrolled
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)
Completed·HHospices Civils de Lyon·Phase 2·NCT03152019·50 enrolled
Tranexamic Acid Dosage for Topical Treatment of Anterior Epistaxis
Completed·—·Phase 4·NCT06183918·152 enrolled
Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis
Completed·KKecioren Education and Training Hospital·Phase 4·NCT03360045·135 enrolled
ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome
Completed·HHospices Civils de Lyon·Phase 3·NCT00355108·170 enrolled
Intranasal Bevacizumab for HHT-Related Epistaxis
Completed·SStanford University·Phase 4·NCT02389959·40 enrolled
Effect of Practical Demonstration to Use Nasal Spray and Apply Intranasal Ointment on Epistaxis
Completed·—·N/A·NCT04217941·300 enrolled
Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Completed·UUnity Health Toronto·N/A·NCT02638012·8 enrolled
Floseal Treatment for Posterior Epistaxis Study
Completed·OOttawa Hospital Research Institute·N/A·NCT01098578·20 enrolled
Epinephrine Nasal Drops for Epistaxis During Nasal Intubation
Completed·UUniversitas Padjadjaran·Phase 2·NCT06789549·40 enrolled
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.
Completed·HHospices Civils de Lyon·Phase 2·NCT03954782·61 enrolled
NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial
Completed·UUniversity of California, Los Angeles·Phase 4·NCT04167085·26 enrolled
Nasal Ointment on Epistaxis of Nasotracheal Intubation in Children
Completed·—·N/A·NCT04426409·108 enrolled
Topical 15% Trichloroacetic Acid Versus Silver Nitrate Cauterization in the Management of Idiopathic Childhood Epistaxis: A Prospective Double-Blinded, Randomized Clinical Trial
Completed·—·N/A·NCT06836791·170 enrolled
Intranasal TXA for Anterior Epistaxis in the Emergency Department
Suspended·MMercy Health Ohio·Phase 2·NCT04054687·86 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)